Venetoclax resistance and acquired mutations in chronic lymphocytic leukemia.
作者信息
Tausch Eugen, Close William, Dolnik Anna, Bloehdorn Johannes, Chyla Brenda, Bullinger Lars, Döhner Hartmut, Mertens Daniel, Stilgenbauer Stephan
机构信息
Department of Internal Medicine III, Ulm University, Ulm, Germany.
Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany.
出版信息
Haematologica. 2019 Sep;104(9):e434-e437. doi: 10.3324/haematol.2019.222588. Epub 2019 Apr 19.
Abstract
摘要
相似文献
1
Venetoclax resistance and acquired mutations in chronic lymphocytic leukemia.
Haematologica. 2019 Sep;104(9):e434-e437. doi: 10.3324/haematol.2019.222588. Epub 2019 Apr 19.
2
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.
3
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
Blood. 2020 Mar 5;135(10):773-777. doi: 10.1182/blood.2019004205.
4
Landscape of Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.
Int J Mol Sci. 2023 Mar 18;24(6):5802. doi: 10.3390/ijms24065802.
5
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Blood. 2020 Jun 11;135(24):2192-2195. doi: 10.1182/blood.2019003722.
6
Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Expert Rev Hematol. 2018 May;11(5):391-402. doi: 10.1080/17474086.2018.1456332. Epub 2018 Mar 29.
7
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.
Nat Commun. 2019 Jun 3;10(1):2385. doi: 10.1038/s41467-019-10363-1.
8
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
Am J Hematol. 2022 Feb 1;97(2):E47-E51. doi: 10.1002/ajh.26411. Epub 2021 Nov 24.
9
Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
Leuk Lymphoma. 2021 May;62(5):1129-1135. doi: 10.1080/10428194.2020.1861278. Epub 2020 Dec 17.
10
Genomics of Resistance to Targeted Therapies.
Hematol Oncol Clin North Am. 2021 Aug;35(4):715-724. doi: 10.1016/j.hoc.2021.03.004. Epub 2021 May 26.
引用本文的文献
1
Biotransformation and disposition of C-labeled sonrotoclax ([C]BGB-11417) in preclinical safety species and characterization of unique contribution from gut microbiome.
Cancer Chemother Pharmacol. 2025 Aug 20;95(1):82. doi: 10.1007/s00280-025-04803-7.
2
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.
Leukemia. 2025 Jun 24. doi: 10.1038/s41375-025-02662-y.
3
upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in rearranged lymphomas.
iScience. 2025 May 2;28(6):112584. doi: 10.1016/j.isci.2025.112584. eCollection 2025 Jun 20.
4
Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era.
Cancers (Basel). 2025 May 7;17(9):1586. doi: 10.3390/cancers17091586.
5
Improving Treatment Options for Patients with Double Refractory CLL.
Cancers (Basel). 2025 Jan 27;17(3):430. doi: 10.3390/cancers17030430.
6
Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention.
Blood Cancer J. 2025 Feb 5;15(1):10. doi: 10.1038/s41408-025-01215-x.
7
BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies.
Front Oncol. 2025 Jan 21;14:1501950. doi: 10.3389/fonc.2024.1501950. eCollection 2024.
8
Emergence of rearrangement and mutations in , , and associated with therapy resistance in chronic lymphocytic leukemia.
EJHaem. 2024 Oct 8;5(6):1265-1268. doi: 10.1002/jha2.1024. eCollection 2024 Dec.
9
BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism.
Lymphatics. 2024 Jun;2(2):50-78. doi: 10.3390/lymphatics2020005. Epub 2024 Mar 28.
10
BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia.
Cells. 2024 Nov 20;13(22):1922. doi: 10.3390/cells13221922.
本文引用的文献
1
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
J Clin Oncol. 2019 Feb 1;37(4):269-277. doi: 10.1200/JCO.18.01580. Epub 2018 Dec 3.
2
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.
3
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1.
4
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.
5
Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
BMC Cancer. 2017 Jun 2;17(1):399. doi: 10.1186/s12885-017-3383-5.
6
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6.
7
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.
Blood. 2014 Jun 26;123(26):4111-9. doi: 10.1182/blood-2014-03-560284. Epub 2014 Apr 30.
8
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.
9
UCSF Chimera--a visualization system for exploratory research and analysis.
J Comput Chem. 2004 Oct;25(13):1605-12. doi: 10.1002/jcc.20084.
Zotero 插件